abstract |
The invention relates to a crystalline erlotinib hydrochloride hydrate and to a process for making crystalline erlotinib anhydrate, which comprises crystallizing an erlotinib hydrochloride hydrate from an aqueous solution of erlotinib hydrochloride; and recrystallizing said erlotinib hydrochloride hydrate from a non-aqueous solvent system to form an anhydrous erlotinib hydrochloride of Form A, Form B, or Form E. |